Orthofix Medical Signals Gradual Turn in Earnings Call

Orthofix Medical Inc. ((OFIX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Orthofix Medical’s latest earnings call struck a cautiously optimistic tone, balancing modest headline growth with signs of improving execution. Management highlighted better gross margins, strong contributions from key distributors and Therapeutic Solutions, and a robust innovation pipeline, while acknowledging lingering softness in Biologics, flat U.S. Limb Reconstruction and modest EBITDA that underscore ongoing operational work.

Total Net Sales and Quarterly Growth

Orthofix reported Q1 2026 global net sales of $196.4 million, reflecting 3% year-over-year growth on a pro forma constant currency basis after excluding discontinued M6 products. Management framed the quarter as a solid start, noting that reported growth was held back by one fewer selling day and timing effects that mask underlying momentum.

Spine Fixation Momentum

Global Spine Fixation net sales rose 6% in constant currency, with U.S. Spine up 4% as distributor transitions largely moved into the rearview mirror. Executives pointed to cleaner channels and better field execution as drivers of this acceleration and see further upside as new navigation and fixation technologies gain wider adoption.

Top Distributor Performance

The company’s strategy of prioritizing larger, dedicated distributors is showing payoff, with its top 30 U.S. partners delivering standout net sales growth of 27% year over year. On a trailing 12‑month basis those same distributors were up 24%, suggesting a durable uplift in productivity that could support more consistent revenue growth.

Therapeutic Solutions Outperformance

Therapeutic Solutions posted net sales of $57.8 million, up 5% year over year, with fracture sales growing 6% and outpacing the broader market. Management highlighted improving utilization and prescribing activity as evidence that this business remains a growth engine and a stabilizing force within the overall portfolio.

Product Innovation and Pipeline

Orthofix underscored its innovation pipeline as a key driver of multi‑year growth, citing full‑year contributions expected from TrueLok Elevate and Fitbone as well as continued differentiation from its 7D FLASH navigation platform. The company also plans a full‑market launch of VIRATA in the second half of 2026, including a minimally invasive alpha rollout aimed at expanding its surgical footprint.

Margin Expansion and Profitability Trajectory

Pro forma non‑GAAP adjusted gross margin improved to 70.7%, a 40 basis point gain versus the prior year that management attributed to mix improvements and cost discipline. Full‑year non‑GAAP adjusted EBITDA guidance of $95–$98 million implies about 70 basis points of margin expansion at the midpoint, signaling a gradual but deliberate profitability build.

Liquidity and Cash Position

The company ended the quarter with $120.9 million in total cash, including restricted cash, and reiterated expectations for positive free cash flow for 2026 excluding potential legal settlements. This liquidity cushion gives Orthofix room to fund its innovation agenda and commercial investments, though investors will watch how much of the improvement is driven by operations versus financing.

Reaffirmed 2026 Guidance and Improving Cadence

Orthofix reaffirmed its full‑year 2026 outlook for net sales of $850–$860 million, implying roughly 5.5% pro forma constant currency growth at the midpoint and an improving cadence from about 5% growth in the first half to around 6% in the second half. Management also maintained guidance for non‑GAAP adjusted EBITDA of $95–$98 million and positive free cash flow, tying the outlook to planned launches such as VIRATA and continued operational execution.

Biologics Softness and Need for Recovery

Biologics remained a weak spot in Q1, underperforming other franchises and acting as a drag on the segment’s overall performance. Leadership changes, including the appointment of Patrick Fisher to lead the business, are intended to reset strategy and execution, but management acknowledged that the anticipated sequential improvement is still ahead rather than in the rearview.

Modest Absolute EBITDA

Despite progress on gross margins, pro forma non‑GAAP adjusted EBITDA for the quarter was only $9.7 million, underscoring modest absolute profitability. Management cited geography mix and lingering commercial transitions as near‑term headwinds, which in turn pressure margin leverage and cash conversion even as the top line grows.

U.S. Limb Reconstruction Headwinds

Global Limb Reconstruction delivered 3% net sales growth to $32.8 million, but U.S. performance was flat as several factors weighed on the quarter. The timing of OSCAR capital equipment sales and the earlier sunsetting of roughly 30 product lines pushed out some growth, delaying the expected reacceleration in this franchise.

Operational Transition and Mix Impacts

The company is still working through residual effects from prior distributor transitions and an unfavorable geography mix that partially offset margin gains. These transitions occurred earlier in the timeline and created tough year‑over‑year comparisons as well as execution challenges in certain channels, though management emphasized they are largely behind the business.

One‑Time and Timing Factors

Quarterly performance was also shaped by several one‑off and timing items, including one fewer selling day that management estimates shaved roughly 1.6% from reported growth. Q1 also benefited by about $2 million from the timing of international stocking orders, which pulled some sales into the quarter and added variability to sequencing across the year.

Increased Leverage to Support Liquidity

The quarter’s cash build reflected not only operations but also a draw on the second tranche of the company’s debt facility, signaling that Orthofix is willing to tap leverage to support liquidity. While this provides flexibility for investments and transitions, it also means investors must factor financing decisions into their assessment of the balance sheet and future cash priorities.

Legal and External Risks

Management’s guidance for positive free cash flow explicitly excludes potential legal settlements, creating an important carve‑out for investors to monitor. Any unfavorable legal outcomes that require cash payments could erode the company’s projected cash generation and complicate efforts to fund growth initiatives without additional financing.

Forward‑Looking Guidance and Outlook

Looking ahead, Orthofix’s reaffirmed guidance rests on a thesis of accelerating growth, incremental margin expansion and improving free cash flow as product launches ramp and operational friction eases. The company’s innovation pipeline and distributor strategy underpin the outlook, but delivery will require Biologics recovery, stronger Limb Reconstruction in the U.S. and careful navigation of legal and financing risks.

Orthofix’s earnings call painted a picture of a company emerging from a transition phase with early proof points but still‑visible pressure points. Investors will likely view the combination of improving margins, strong distributor performance and reaffirmed guidance as constructive, while keeping a close eye on Biologics, Limb Reconstruction and cash generation to confirm that the improving momentum can be sustained.